President Emeritus

Prof Gavin Churchyard

Prof Churchyard is an NRF A-rated scientist and a specialist physician, internationally renowned for his contributions in tuberculosis (TB). He is the founder and President Emeritus of The Aurum Institute NPC, an independent, public benefit organisation that focuses on TB and HIV service delivery, management and research.

He is an Honorary Professor at the University of Witwatersrand, School of Public Health and an Honorary Professor at the London School of Hygiene and Tropical Medicine.

Publications

44 publications

From 2025 and 2026

2026

Guiding principles for pragmatic randomised trials of tuberculosis treatments

Phillips PPJ, Schumacher SG, Cassino C, Charalambous S, Chaisson RE, Churchyard GJ, et al.

Lancet Infect Dis. 2026 Aug 14:S1473-3099(26)00359-2.

View publication (opens in a new tab)
2026

Inflammatory biomarkers of asymptomatic and symptomatic tuberculosis

Awany D, Ariefdien DT, Mendelsohn SC, Rozot V, Mulenga H, Nyangu S, et al.

Also an author: Churchyard G

Nat Commun. 2026 Jul 25;17(1):9079.

View publication (opens in a new tab)
2026

New tuberculosis vaccines for people with HIV

Sumner T, Clark RA, Prys-Jones TO, Bakker R, Churchyard G, White RG

AIDS. 2026 Jul 23.

View publication (opens in a new tab)
2026

Towards culture-free sequencing of Mycobacterium tuberculosis: evaluating new targeted and whole-genome approaches for genotyping and drug resistance profiling

Iannucci I, Di Marco F, Moghaddasi K, Miotto P; *POR TB study group; Cabibbe AM, Cirillo DM

Genome Med. 2026 Jul 21. *Churchyard G, a member of POR TB study Group.

View publication (opens in a new tab)
2026

The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design

Dagnew AF, Schmidt AC, Cinar A, Garcia-Basteiro AL, Noble R, Pelzer PT, et al.

Also an author: Churchyard GJ

Vaccine. 2026 Jun 10;88:128822.

View publication (opens in a new tab)
2026

Inclusion of young adolescents in policy development for new tuberculosis vaccines

Hatherill M, Clark RA, Martinez L, Fiore-Gartland AL, Garcia-Basteiro AL, Churchyard GJ, et al.

Lancet Glob Health. 2026 Jun 8:S2214-109X(26)00017-3.

View publication (opens in a new tab)
2026

A proteome-wide atlas of humoral immunity to Mycobacterium tuberculosis across the spectrum of disease

Khan MZ, Irvine EB, Cizmeci D, Davies LRL, Randall AZ, Pablo J, et al.

Also an author: Churchyard G

Front Immunol. 2026 Jun 3;17:1810894.

View publication (opens in a new tab)
2026

Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment at conception and during first trimester in women living with HIV: a secondary analysis of WHIP3TB trial

Chihota V, Waggie Z, Cardenas V, Mngadi K, Ndebele F, Brumskine W, et al.

Also an author: Churchyard G

Clin Infect Dis. 2026 May 17:ciag315.

View publication (opens in a new tab)
2026

Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01E-4 tuberculosis vaccine

Dagnew AF, Noble R, Cinar A, Burhan E, Churchyard G, Fairlie L, et al.

Vaccine. 2026 May 12;85:128690.

View publication (opens in a new tab)
2026

Real-time electronic drug monitoring: experiences from a multinational phase 3 clinical trial to prevent multidrug-resistant TB

Jimah T, Haberer JE, Amico KR, Tinkamanyire J, Kendall MA, Moonsamy S, et al.

Also an author: Churchyard G

IJTLD Open. 2026 May 11;3(5):305-311.

View publication (opens in a new tab)
2026

Restoring certainty to global health regulation

Yang YT, Perehudoff K, Tran B, Churchyard G

BMJ. 2026 May 6;393:s814.

View publication (opens in a new tab)
2026

Threshold cost of delivering preventive treatment for household contacts of people with multidrug-resistant TB

Young N, Lee JH, Gupta A, Churchyard G, Hesseling AC, Swindells S, et al.

Int J Tuberc Lung Dis. 2026 Apr 27;30(5):225-227.

View publication (opens in a new tab)
2026

Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial

Van Rie A, Conceição EC, Ndebele F, Wells F, Paulse A, Mekonnen EG, et al.

Also an author: Churchyard G

Lancet Respir Med. 2026 Apr 20: S2213-2600(26)00095-0.

View publication (opens in a new tab)
2026

Dynamics of Quantiferon-Gold Plus results in a large TB preventive treatment trial across three high-burden HIV/TB countries

Saavedra-Cervera B, Nguenha D, Chihota V, Yimer G, Fernández-Escobar C, Mngadi K, et al.

Also an author: Churchyard G

J Infect Dis. 2026 Mar 17:jiag165.

View publication (opens in a new tab)
2026

Targeted and whole-genome sequencing for drug resistance and genetic relatedness inference of rifampicin-resistant Mycobacterium tuberculosis: an in-depth comparison

de Diego Fuertes M, Costa Conceição E, Wells F, Rennie V, Heupink T, Churchyard G, et al.

ERJ Open Res. 2026 Feb 23;12(1):00630-2025.

View publication (opens in a new tab)
2026

Imprecision in tuberculosis infection outcomes: implications for non-inferiority vaccine trials

Grint DJ, White RG, Churchyard G, Fiore-Gartland A, Rangaka M, Garcia-Basteiro AL, Cobelens F

Int J Epidemiol. 2026 Feb 18;55(2):dyag034.

View publication (opens in a new tab)
2026

Risk factors for immunological sensitization to Mycobacterium tuberculosis and progression to incident TB disease among HIV-uninfected adults in a high burden setting

Mulenga H, Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Musvosvi M, Tameris M, et al.

Also an author: Churchyard G

J Infect Dis. 2026 Feb 18:jiag100.

View publication (opens in a new tab)
2026

Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study

Tanvir H, Clark RA, Sumner T, Horton KC, Prŷs-Jones TO, Bakker R, et al.

Also an author: Churchyard GJ

PLoS Med. 2026 Feb 12;23(2):e1004595.

View publication (opens in a new tab)
2026

Optimized Mass Spectrometry to Uncover M. tuberculosis Biomarkers in Extracellular Vesicles from Asymptomatic Tuberculosis Patients

Nieto Ramirez LM, Shelton K, Belisle JT, Diaz G, Tameris M, Naidoo K, et al.

Also an author: Churchyard G

J Infect Dis. 2026 Feb 10:jiag086.

View publication (opens in a new tab)
2026

Insights on the implementation strategies for a potential new tuberculosis vaccine in South Africa

Thomas KA, Okoro C, Ntshiqa T, Damovsky V, Goldberg D, Ramokhoase O, et al.

Also an author: Churchyard GJ

PLOS Glob Public Health. 2026 Jan 30;6(1):e0005047.

View publication (opens in a new tab)
2025

Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients: Study protocol for the PHOENIx phase 3 clinical trial

Kendall MA, Hughes MD, Kim S, Aaron LA, Naini L, Suryavanshi N, et al.

Also an author: Churchyard GJ

Contemp Clin Trials. 2025 Sep 22;158:108084.

View publication (opens in a new tab)
2025

Preventing multidrug resistant tuberculosis: the dawn of a new era

Churchyard GJ, Swindells S, Gupta A, Shah NS, Hughes M, Kim S, et al.

Clin Inf Dis 2025 Aug 7:ciaf426.

View publication (opens in a new tab)
2025

An evaluation of a choice architecture-based intervention on prescribing of TB preventive treatment to people living with HIV in southern Africa (the CAT study): a cluster-randomised trial

Shearer K, Nonyane BAS, Mulder C, Kaonga E, Nyirenda R, Mbendera K, et al.

Also an author: Churchyard GJ

BMJ Glob Health. 2025 May 24;10(5):e016921.

View publication (opens in a new tab)
2025

Effectiveness of a Home-based Approach to Child Contact Investigation and TPT Management by Community Health Workers in Ethiopia: A Pragmatic Cluster-randomized Trial

Salazar-Austin N, Cohn S, Nonyane BAS, Mulder C, Mulatu F, Bayu S, …, Golub JE, Chaisson RE, Churchyard G, Bedru A

Clin Infect Dis. 2025 May 16: ciaf203.

View publication (opens in a new tab)
2025

Neuromyelitis optica causing vision loss during TB treatment with sutezolid: evidence of aberrant immunity following infection

Glover NA, Paramo L, Giangregorio S, Sukwana B, Koele SE, Charalambous S, et al.

Also an author: Churchyard G

IJTLD Open. 2025 May 12;2(5):306-309.

View publication (opens in a new tab)
2025

Resistance to tuberculin skin test/interferon-gamma release assay conversion among highly TB exposed, HIV infected goldminers in South Africa

Ntshiqa T, Velen K, Ginindza S, Nhlangulela L, Charalambous S, Hawn TR, et al.

Also an author: Churchyard G

PLoS One. 2025 May 9;20(5):e0318819.

View publication (opens in a new tab)
2025

Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial

Weld ED, Beattie T, Moodley J, Mapendere M, Salles I, Solans BP, et al.

Also an author: Churchyard GJ

Lancet HIV. 2025 May 8:S2352-3018(25)00002-5.

View publication (opens in a new tab)
2025

Cost and cost-effectiveness of pediatric home-based versus facility-based TB Preventive Treatment in Ethiopia (CHIP-TB)

Malhotra A, Bedru A, Mulatu F, Nonyane BAS, Cohn S, Mulder C, et al.

Also an author: Churchyard G

PLOS Glob Pub Health. 2025 Apr 30;5(4):e0004466.

View publication (opens in a new tab)
2025

Deciphering HIV vaccine-induced Antibody response according to ethnicity

Lin LY, Ferte T, Chachage M, Casteano C, Laumond G, Schmidt S, et al.

Also an author: Churchyard G

AIDS. 2025 Mar 31.

View publication (opens in a new tab)
2025

Unveiling a hidden phenotype of early tuberculosis

Ehrlich J, Suñer C, Churchyard G, Cobelens F, Hatherill M, Mendelsohn SC, et al.

Lancet Respir Med. 2025 Mar 21:S2213-2600(25)00092-X.

View publication (opens in a new tab)
2025

Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial

Borges ÁH, Russell M, Tait D, Scriba TJ, Nemes E, Skallerup P, et al.; POR TB study group

Also an author: Churchyard G

Lancet Infect Dis. 2025 Mar 5:S1473-3099(24)00814-4.

View publication (opens in a new tab)
2025

The potential impact of new tuberculosis vaccines on the burden of tuberculosis in people with HIV in South Africa

Sumner T, Clark RA, Prys-Jones TO, Bakker R, Churchyard G, White RG

AIDS. 2025 Feb 1;39(2):175-183.

View publication (opens in a new tab)
2025

BMI as a predictor of progression from TB infection to active TB in PLHIV

Nguenha D, Ndebele F, Saavedra B, Mambuque E, Acácio S, Cárdenas V, et al.

Also an author: Churchyard G

Int J Tuberc Lung Dis. 2025 Feb 1;29(2):54-59.

View publication (opens in a new tab)
2025

N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis

Mapamba DA, Sabi I, Lalashowi J, Sauli E, Buza J, Olomi W, et al.

Also an author: Churchyard G

J Infect. 2025 Jan 3;90(2):106379.

View publication (opens in a new tab)
2025

Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data

Pelzer PT, Stuck L, Martinez L, Richards AS, Acuña-Villaorduña C, Aronson NE, et al.

Also an author: Churchyard G

Lancet Microbe. 2025 Feb;6(2):100961.

View publication (opens in a new tab)
2025

Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review

Chihota V, Gombe M, Gupta A, Salazar-Austin N, Ryckman T, Hoffmann CJ, et al.

Also an author: Churchyard G

Drugs. 2025 Feb;85(2):127-147.

View publication (opens in a new tab)
2025

Frequency of tuberculosis symptoms at repeat visits amongst adults attending for HIV care in Gauteng province, South Africa

Ntshiqa T, Jawad S, Hanifa Y, Chihota V, Charalambous S, Ndlovu N, et al.

Also an author: Churchyard G

BMC public health 2025; 25: 3667.

View publication (opens in a new tab)
2025

Optimising child-friendly TB preventive treatment regimens

Mulder C, Bergman AJ, Mulatu F, Chaisson R, Churchyard G, Bedru A, et al.

IJTLD Open 2025; 2: 671-676.

View publication (opens in a new tab)
2025

Treatment completion and challenges in rolling out 12-dose weekly rifapentine plus isoniazid to prevent tuberculosis among people living with HIV and pediatric household contacts in Brazil

Salles I, Garcia de Oliveira J, Brito de Souza A, Cohn S, Spener-Gomes R, Dourado de Andrade S, et al.

Also an author: Churchyard G

J Bras Pneumol.2025;51(4):e20250125.

View publication (opens in a new tab)
2025

Epidemiological factors associated with immunological resistance in household contacts exposed to active tuberculosis in South Africa: A logistic regression analysis

Maenetje N, Oladimeji M, Mlotshwa M, Hoft D, Lindan C, Wallis R, et al.

Also an author: Churchyard G

PLoS One 2025; 20: e0329562.

View publication (opens in a new tab)
2025

Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants

Cobelens F, Pelzer PT, Churchyard GJ, Garcia-Basteiro A, Hatherill M, Hill PC, et al.

Vaccine 2025; 61: 127301.

View publication (opens in a new tab)
2025

The participation of people deprived of liberty in tuberculosis vaccine trials: should they be protected from research, or through research?

Andrews JR, Charalambous S, Churchyard G, Cobelens F, Fernández-Escobar C, Frick M, et al.

Lancet Infect Dis 2025.

View publication (opens in a new tab)
2025

Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials

White RG, Churchyard GJ, Horton KC, Fiore-Gartland A, Behr MA, Clark RA, et al.

Lancet Resp Med 2025.

View publication (opens in a new tab)
2025

The delivery of new tuberculosis vaccines to people living with HIV - when to vaccinate?

Sumner T, Clark RA, Prys-Jones TO, Bakker R, Churchyard G, White RG

BMC Infect Dis 2025; 25: 878.

View publication (opens in a new tab)

44 publications

Guiding principles for pragmatic randomised trials of tuberculosis treatments

Inflammatory biomarkers of asymptomatic and symptomatic tuberculosis

New tuberculosis vaccines for people with HIV

Towards culture-free sequencing of Mycobacterium tuberculosis: evaluating new targeted and whole-genome approaches for genotyping and drug resistance profiling

The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design

Inclusion of young adolescents in policy development for new tuberculosis vaccines

A proteome-wide atlas of humoral immunity to Mycobacterium tuberculosis across the spectrum of disease

Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment at conception and during first trimester in women living with HIV: a secondary analysis of WHIP3TB trial

Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01E-4 tuberculosis vaccine

Real-time electronic drug monitoring: experiences from a multinational phase 3 clinical trial to prevent multidrug-resistant TB

Restoring certainty to global health regulation

Threshold cost of delivering preventive treatment for household contacts of people with multidrug-resistant TB

Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial

Dynamics of Quantiferon-Gold Plus results in a large TB preventive treatment trial across three high-burden HIV/TB countries

Targeted and whole-genome sequencing for drug resistance and genetic relatedness inference of rifampicin-resistant Mycobacterium tuberculosis: an in-depth comparison

Imprecision in tuberculosis infection outcomes: implications for non-inferiority vaccine trials

Risk factors for immunological sensitization to Mycobacterium tuberculosis and progression to incident TB disease among HIV-uninfected adults in a high burden setting

Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study

Optimized Mass Spectrometry to Uncover M. tuberculosis Biomarkers in Extracellular Vesicles from Asymptomatic Tuberculosis Patients

Insights on the implementation strategies for a potential new tuberculosis vaccine in South Africa

Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients: Study protocol for the PHOENIx phase 3 clinical trial

Preventing multidrug resistant tuberculosis: the dawn of a new era

An evaluation of a choice architecture-based intervention on prescribing of TB preventive treatment to people living with HIV in southern Africa (the CAT study): a cluster-randomised trial

Effectiveness of a Home-based Approach to Child Contact Investigation and TPT Management by Community Health Workers in Ethiopia: A Pragmatic Cluster-randomized Trial

Neuromyelitis optica causing vision loss during TB treatment with sutezolid: evidence of aberrant immunity following infection

Resistance to tuberculin skin test/interferon-gamma release assay conversion among highly TB exposed, HIV infected goldminers in South Africa

Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial

Cost and cost-effectiveness of pediatric home-based versus facility-based TB Preventive Treatment in Ethiopia (CHIP-TB)

Deciphering HIV vaccine-induced Antibody response according to ethnicity

Unveiling a hidden phenotype of early tuberculosis

Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial

The potential impact of new tuberculosis vaccines on the burden of tuberculosis in people with HIV in South Africa

BMI as a predictor of progression from TB infection to active TB in PLHIV

N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis

Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data

Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review

Frequency of tuberculosis symptoms at repeat visits amongst adults attending for HIV care in Gauteng province, South Africa

Optimising child-friendly TB preventive treatment regimens

Treatment completion and challenges in rolling out 12-dose weekly rifapentine plus isoniazid to prevent tuberculosis among people living with HIV and pediatric household contacts in Brazil

Epidemiological factors associated with immunological resistance in household contacts exposed to active tuberculosis in South Africa: A logistic regression analysis

Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants

The participation of people deprived of liberty in tuberculosis vaccine trials: should they be protected from research, or through research?

Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials

The delivery of new tuberculosis vaccines to people living with HIV - when to vaccinate?